Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-003 in Acute Graft-Versus-Host Disease (aGVHD)
NCT07070674Phase 1Completed
- Sponsor
- Accro Bioscience
- Start
- Jul 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AC-003 in Acute Graft-Versus-Host Disease (aGvHD) (4 cohorts), sponsored by Accro Bioscience. Primary endpoint: Incidence and severity of Adverse Events. Started Jul 2024; status: completed.
02
Drugs
AC-003
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07070674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070674.